2006-2020年英国伴与不伴慢性肾脏病的2型糖尿病患者降糖药物处方偏好趋势
该回顾性队列研究利用英国临床实践研究数据链(2006-2020),评估伴慢性肾脏病(n=38,622)与不伴慢性肾脏病(n=230,963)的2型糖尿病患者降糖药物起始治疗模式。二甲双胍起始总体下降但仍是两组首选一线治疗;SGLT2i使用在伴CKD患者中仅 modest 增加,在不伴CKD患者中增加更明显;到2020年,不伴CKD患者相比伴CKD患者,总体和作为二线治疗起始SGLT2i的可能性分别高3倍(28.5% vs 9.4%)和6倍(46.3% vs 7.9%)。GLP-1RA使用在两组均极少(<5%),而DPP4i和磺脲类在伴CKD患者中仍保持较高使用。
要点
- 二甲双胍起始总体下降,但仍是伴与不伴CKD的2型糖尿病患者的首选一线治疗。
- 到2020年,不伴CKD患者相比伴CKD患者,总体起始SGLT2i的可能性高3倍(28.5% vs 9.4%)。
- 到2020年,不伴CKD患者相比伴CKD患者,作为二线治疗起始SGLT2i的可能性高6倍(46.3% vs 7.9%)。
核心结论
- SGLT2i使用在2型糖尿病患者中增加,但这一增加主要由不伴CKD的患者驱动。
- 需要开展工作以识别伴CKD患者中与已被证实具有心肾获益的疗法(如SGLT2i、GLP-1RA) uptake 相关的障碍。
研究设计与样本
- 回顾性队列研究,使用英国临床实践研究数据链(2006-2020)。
- 纳入伴CKD的2型糖尿病患者n=38,622和不伴CKD的2型糖尿病患者n=230,963。
- 评估总体、一线及二线(二甲双胍之后)降糖药物起始治疗模式。
主要发现
- 相对于其他降糖疗法,二甲双胍起始总体下降,但仍是伴与不伴CKD患者的首选一线治疗。
- SGLT2i使用在伴CKD患者中适度增加,但在不伴CKD患者中增加更明显。
- 到2020年,不伴CKD患者相比伴CKD患者,总体起始SGLT2i的可能性高3倍(28.5% vs 9.4%)。
- 到2020年,不伴CKD患者相比伴CKD患者,作为二线治疗起始SGLT2i的可能性高6倍(46.3% vs 7.9%)。
- GLP-1RA使用在两组均极少(<5%);到2020年,伴CKD患者中DPP4i和磺脲类分别占所有起始的28.3%和20.6%,占二线起始的57.4%和30.3%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate trends in antidiabetic medication initiation patterns among patients with type 2 diabetes mellitus (T2DM) with and without chronic kidney disease (CKD). RESEARCH DESIGN AND METHODS: A retrospective cohort study using the UK Clinical Practice Research Datalink (2006-2020) was conducted to evaluate the overall, first-, and second line (after metformin) medication initiation patterns among patients with CKD (n = 38,622) and those without CKD (n = 230,963) who had T2DM. RESULTS: Relative to other glucose-lowering therapies, metformin initiations declined overall but remained the first-line treatment of choice for both patients with and those without CKD. Sodium-glucose cotransporter-2 (SGLT2i) use increased modestly among patients with CKD, but this increase was more pronounced among patients without CKD; by 2020, patients without CKD, compared with patients with CKD, were three (28.5% vs. 9.4%) and six (46.3% vs. 7.9%) times more likely to initiate SGLT2i overall and as second-line therapy, respectively. Glucagon-like peptide 1 receptor agonist (GLP-1RA) use was minimal regardless of CKD status (<5%), whereas both dipeptidyl peptidase-4 inhibitor (DPP4i) and sulfonylurea use remained high among patients with CKD. For instance, by 2020, and among patients with CKD, DPP4i and sulfonylureas constituted 28.3% and 20.6% of all initiations, and 57.4% and 30.3% of second-line initiations, respectively. CONCLUSIONS: SGLT2i use increased among patients with T2DM, but this increase was largely driven by patients without CKD. Work is needed to identify barriers associated with the uptake of therapies with proven cardiorenal benefits (e.g., SGLT2i, GLP-1RA) among patients with CKD.
引用
- Liaw J, Harhay M, Setoguchi S, et al. Trends in Prescribing Preferences for Antidiabetic Medications Among Patients With Type 2 Diabetes in the U.K. With and Without Chronic Kidney Disease, 2006-2020. Diabetes Care. 2022. PMID: 35984049. doi:10.2337/dc22-0224
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。